findings are used to define the protocol survey and the indications for substitution treatment, and to propose a protocol for re-evaluating ovarian function to detect ovarian Ovarian failure is often brought about by the conditioning protocol used for bone marrow transplantation recovery. (BMT). We monitored ovarian function in 31 girls conditioned for BMT at 10.3 ؎ 0.6 (s.e., 3.2-17.5) years by chemotherapy alone (group 1, n = 8) or chemotherapy Patients and methods plus body irradiation (12 Gy, fractionated in group 2, n = 9, or 10 Gy single total body in group 3, n = 7, and A group of 31 girls who underwent BMT at 3.2-17.5 years were seen at 11.7-18.6 years at the Pediatric Endocrinology 5 or 6 Gy single thoraco-abdominal in group 4, n = 7, irradiation) at 13.4 ؎ 0.4 (11.7-18.6) years. Breast
). ovarian failure in girls receiving BMT during childhood, Ovarian function was assessed by spontaneous breast resulting in insufficient growth and sexual development at development, the occurrence of menstruation, and measurepuberty and sterility in adulthood. Their follow-up includes ment of basal plasma estradiol concentrations in patients helping them to attain a better adult height by giving with spontaneous breast development and gonadotrophins adequate substitutive treatment, 1 assuring their female (follicle-stimulating hormone (FSH) and luteinizing hordevelopment and regular menses, and informing them about mone (LH)) concentrations in all but cases 1 and 2. Patients their capacity to become pregnant. Most girls who have with no breast development or enlargement and increased undergone BMT, particularly body irradiation, have ovarian gonadotropin concentrations were given oral ethinyl estrafailure, but the ovaries can recover and fertility is possible. were also monitored. Group 1 and cases 9, 10, 14, 16 and 17 were given BMT at Institut Curie and the others at Hopital Saint Louis. TBI = total body irradiation; TAI = thoraco-abdominal irradiation; ALL = acute lymphoblastic leukemia; AML = acute myelogenous leukemia; SAA = severe aplastic anemia; m = menstruation; 1 = cyclophosphamide; 2 = busulfan; 3 = BCNU; 4 = etoposide; 5 = cytarabine; 6 = melphalan; 7 = carboplatin.
Results (Table 1) 29 patients evaluated and LH in 23/29. The plasma FSH and LH concentrations of four patients with regular spontaneous menstruation were measured twice (cases 3, 9, 26 At the time of BMT, of the 31 patients, 24 were prepubertal, seven patients (cases 3-8 and 31) had began puberty, and 29). They had returned to normal values at the second evaluation. and four (cases 4, 6-8) had begun menstruating. After BMT, breast development began in 10 patients (cases 1, 2, At the last clinical evaluation performed after an interval after irradiation of 6 ± 0.5 (1.2-11.5) years, six patients 9, 12, 18, 19, 21, 26, 27 and 29) or continued to progress spontaneously (case 3). Menstruation occurred in eight and (cases 1-3, 9, 26 and 29) had normal clinical ovarian function with regular spontaneous menstruation and normal three did not menstruate (cases 12, 18 and 21). Fourteen patients had no spontaneous breast development, two (cases plasma FSH and LH in the four evaluated, two patients (cases 19 and 27) had partial ovarian failure with spon-5 and 31) showed no continued breast development, and all four menstruating patients went into permanent taneous breast development, irregular menstruation and increased plasma FSH and LH concentrations, and 23 amenorrhea.
Basal plasma FSH concentrations were increased in all patients had no spontaneous estrogen activity. (Table 3 ). The reported data suggest that young age at TBI and a fractionated protocol are significantly associated with increased ovarian recovery. Patients given 12 Gy fractionIt is important to assess the capacity of girls undergoing BMT during childhood to produce spontaneous estrogenic ated TBI were 4.8 times more likely to have a return of normal ovarian function when compared with patients who activity at puberty. Estrogen secretion is needed for breast development and for the growth acceleration which norreceived other TBI exposures. 11 Ovarian recovery makes possible spontaneous menstruation and pregnancy, but the mally occurs at puberty. 3 Height gain during puberty accounts for 16% of total adult height. Body irradiation time required for this recovery may vary. Sanders et al 11 reported the return of menstrual cycles 0.25-3.5 years after may be followed by a great reduction in adult height. Many factors are involved in this, including the initial disease, the cyclophosphamide and 3-7 years after TBI, with an actuarial probability of recovery of 0.24 at 7 years in these complications of BMT, and/or the long-term corticosteroid therapy required to treat these complications. The other two cases. Spinelli et al 7 found the interval to be 1.8-7.2 years, with an actuarial probability of recovery of 0.35 at 10 years. main factors are the reduction in growth hormone secretion due to hypothalamic-pituitary irradiation and the skeletal However, only 1/73 patients given cyclophosphamide (200 mg/kg) and busulfan (16 mg/kg) recovered ovarian lesions induced by bone irradiation. 1 These lesions result in a poor response to growth hormone treatment, leading function. 2 All patients in the present study who were given busulfan suffered ovarian failure. Transient increases in to very short adult height in some patients. It is therefore important to give the girls with ovarian failure estrogen plasma gonadotrophins, such as those that occurred in four patients of this study, have also been reported. 9 These data treatment at the appropriate time they need to reach their best adult height. The basal plasma FSH and LH of the suggest that estrogen-progestin substitution in girls having ovarian failure due to BMT should be stopped for 2 months patients whose growth was monitored after body irradiation, were measured when their chronological age at regular intervals to detect any ovarian recovery. The first interruption should be at around 1 year after BMT for those was 11-12 years, and slightly later in those with bone age retardation, short stature, or producing catch-up growth due given chemotherapy alone, and at around 3 years for those given chemotherapy plus TBI. In a study of 82 prepubertal to growth hormone treatment. Basal plasma estradiol is not routinely evaluated in the girls who had no breast developgirls who underwent BMT and were aged over 12 years at evaluation, 23 (28%) girls developed normal ovarian funcment, as it is expected to be in the prepubertal range. Patients who had no breast development or enlargement tion, and among them, nine became pregnant. 2 All the pregnancies of the five who were given TBI terminated with and increased basal plasma FSH and LH are given oral ethinyl estradiol (2 g/day) until the end of their growth. spontaneous abortion. There is an increased frequency of low birth weights in females given abdominal irradiation They were monitored by the pediatric endocrinologist, during this period and then by the pediatric gynaecologist. The for Wilms' tumor during childhood 12 and in those given TBI after puberty.
Discussion
2 This is attributed to fibrosis and alterestrogen dose was increased and given cyclically with progestin to induce regular menstruation.
ations of the vascularization of the myometrium. The frequency of congenital malformations is unchanged. No Risk factors for ovarian failure in girls undergoing BMT are difficult to analyze because of the variety of conditioninformation is available on the aborted products of conception, leaving the question of the contributions of ovarian ing regimens used and differences in the patients' ages ( Table 2 , Refs 4-10). The eight girls who had been menand uterine lesions unanswered, although these may be more marked in girls given TBI before puberty. struating spontaneously in this study were given chemotherapy alone, excluding busulfan (three cases), or chemotherapy plus body irradiation at a young age.
Ovarian recovery also depends on conditioning regimen 
